Pharmacokinetics
SOLID TUMORS
The pharmacokinetic-evaluable population for tusamitamab ravtansine included 26 patients from cohort Q2W-LD and 15 patients from cohort Q3W. After the first administration, tusamitamab ravtansine plasma concentrations remained quantifiable up to day 14 in the Q2W-LD cohort (Pharmacokinetic profile of tusamitamab ravtansine during the first cycle of treatment in patients with advanced solid tumors. Plasma concentration over time is shown for patients receiving an LD (120–170 mg/mExposure to tusamitamab ravtansine (maximum plasma concentration, Clearance ranged from approximately 0.4 to 0.7 L/day, and the terminal elimination half-life ranged from approximately 6 to 8 days across all DLs in cohorts Q2W-LD and Q3W (